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Braina b s t r a c t
In this study we examined the impact of systemic treatment with the long-acting brain penetrant b2-
adrenoceptor agonist clenbuterol on NFjB activity and IjB expression in rat brain. Clenbuterol decreased
NFjB activity (p65 DNA binding) in nuclear extracts prepared from rat cortex and hippocampus for up to
8 h following a single treatment. This was accompanied by increased expression of IjBa mRNA and pro-
tein. The temporal increase in IjB protein expression paralleled the suppression of NFjB activity, sug-
gesting that IjBa mediates the suppression NFjB activity observed. These actions of clenbuterol were
prevented by pre-treatment with the non-selective b-adrenoceptor antagonist propranolol, the b2-adre-
noceptor antagonist ICI-118,551, but not the b1-adrenoceptor antagonist metoprolol, suggesting that the
effects of clenbuterol on IjBa expression and NFjB activity are mediated specifically by the b2-adreno-
ceptor. In addition, the actions of clenbuterol were mimicked by systemic administration of another
highly selective long-acting b2-adrenoceptor agonist formoterol. As neurodegenerative diseases are asso-
ciated with inflammation we determined if clenbuterol could suppress NFjB activation that occurs in
response to an inflammatory stimulus. In this regard we demonstrate that clenbuterol inhibited IjB
phosphorylation and IjB degradation and inhibited NFjB activity in hippocampus and cortex of rats fol-
lowing a central injection of the inflammagen bacterial lipopolysaccharide (LPS). In tandem, clenbuterol
blocked expression of the NFjB-inducible genes TNF-a and ICAM-1 following LPS administration. Our
finding that clenbuterol and formoterol inhibit NFjB activity in the CNS further supports the idea that
b2-adrenoceptors may be an attractive target for treating neuroinflammation and combating inflamma-
tion-related neurodegeneration.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Neuroinflammation, characterized by inappropriate microglial
activation and inflammatory mediator production, contributes to
the pathophysiology of neurodegenerative states such as Alzhei-
mer’s disease, Parkinson’s disease and ischaemic stroke (Allan
et al., 2005; Block et al., 2007; Heneka and O’Banion, 2007). Despite
the evidence that the neurotransmitter noradrenaline elicits
endogenous anti-inflammatory actions in the brain mediated by
glial b2-adrenoceptors (Feinstein et al., 2002; Heneka et al., 2002;
Kalinin et al., 2007; McNamee et al., 2010a; Mori et al., 2002),
the anti-inflammatory effects of agents that directly stimulatethe b2-adrenoceptor in the central nervous system (CNS) have
not been extensively studied to date.
The brain-penetrant b2-adrenoceptor agonist clenbuterol is
used in the treatment of respiratory disorders including asthma
and chronic obstructive pulmonary disease (COPD) (Baronti et al.,
1980; Erichsen et al., 1994; Tondo et al., 1985; Papiris et al.,
1986; Boner et al., 1988) and more recently it has been shown to
have neuroprotective properties both in vivo and in vitro (Culmsee
et al., 1999a,b). Specifically, clenbuterol has neuroprotective ac-
tions in rodent models of cerebral ischaemia (Semkova et al.,
1996; Zhu et al., 1998; Culmsee et al., 1999b; Junker et al., 2002)
and in both in vitro and in vivo models of excitotoxicity (Semkova
et al., 1996; Gleeson et al., 2010). It has recently been demon-
strated that clenbuterol induces expression of the pro-inflamma-
tory cytokine IL-1b and its negative regulators IL-1ra and IL-1RII
in rat brain and reduces expression of IL-6 and TNF-a (McNamee
et al., 2010c). In addition, clenbuterol induces expression of the
broad spectrum anti-inflammatory cytokine IL-10 and its
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et al., 2010b), and thus may be effective in the treatment of neur-
oinflammatory disease.
The transcription factor nuclear factor kappa-B (NFjB) is respon-
sible for the regulation of genes encoding a variety of proteins in-
volved in driving the immune response, such as cytokines,
chemokines, and adhesion molecules (Subramaniam et al., 2004).
It is composed of various dimeric complexes containing members
of the Rel protein family, which include Rel (c-Rel), Rel A (p65), RelB,
NF-jB1 (p50 and its precursor p105) and NF-jB2 (p52 and its pre-
cursor p100) (Ghosh et al., 1998). Themost commondimeric combi-
nation is composed of the p50 and p65 subunits (Moynagh, 2005).
In the resting cell, NFjB resides in the cytoplasm where it is
bound to the inhibitory molecule IjB, the most common forms
being IjBa and to a lesser extent IjBb (Ghosh et al., 1998). This
interaction sequesters NFjB in the cytoplasm and inhibits its
DNA-binding activity. Upon stimulation by a range of signals, such
as bacterial lipopolysaccharide (LPS), pro-inflammatory cytokines
and ultraviolet light, IjBa is phosphorylated and subsequently de-
graded by the 26S proteasome (Karin and Ben-Neriah, 2000). Degra-
dation of IjBa releases NFjB allowing it to translocate to the
nucleus where it regulates the expression of numerous genes in-
volved in inflammation as well as IjBa (Karin and Ben-Neriah,
2000;Minagar et al., 2002; Simi et al., 2005). Notably, IjBa is rapidly
re-synthesized following NFjB activation due to the presence of a
transcriptional binding site for IjB on the NFjB promoter (Sun
et al., 1993). Newly synthesized cytoplasmic IjBa translocates to
the nucleuswhere it terminates the activity of NFjB by transporting
it back to the cytoplasm (Arenzana-Seisdedos et al., 1995, 1997).
This is a critical inhibitory stepwhich results in transient NFjB acti-
vation and restoration of cytoplasmic pools of inactive NFjB.
In the present investigation we examined the effect of treat-
ment with the b2-adrenoceptor agonist clenbuterol on NFjB activ-
ity in the rat cortex and hippocampus. We chose the cortex and
hippocampus for analysis in these studies as both regions receive
rich noradrenergic innervation from the locus coeruleus (Dahl-
ström and Fuxe, 1964), and are involved in higher cognitive pro-
cessing such as learning, memory and reasoning that are
adversely affected in many neurodegenerative diseases (Burton
et al., 2004; Whitwell et al., 2007). Specifically, we investigated
the effects of clenbuterol on NFjB activity (by measuring the
DNA binding activity of the NFjB p65 subunit in nuclear extracts),
on IjBa and IjBb mRNA expression and on cytoplasmic IjBa pro-
tein levels. Additionally, we studied the involvement of the b2-
adrenoceptor in these processes, examining the ability of b-adre-
noceptor antagonists (Non-selective: propranolol; b2; ICI-
118,551; b1: metoprolol) to block, and the ability of a related b2-
adrenoceptor agonist, formoterol, to mimic the actions of clenbu-
terol on NFjB activity in rat brain. As neurodegenerative diseases
are associated with a neuroinflammatory state (Heneka and O’Ban-
ion, 2007). We determined if b2-adrenoceptor activation could in-
hibit NFjB activation and induction of NFjB-inducible genes that
occurs in response to an inflammatory stimulus (intracerebroven-
tricular challenge bacterial lipopolysaccharide; LPS).2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats (200–250 g) were obtained from
Harlan, UK. Rats were maintained on a 12 h light: 12 h dark cycle
(lights on at 08:00 h) in a temperature controlled room
(22 ± 2 C) and food and water were available ad libitum. The
experimental protocols were in compliance with the European
Communities Council directive (86/609/EEC).2.2. Drugs
Clenbuterol and LPS (Escherichia coli: serotype 0111:B4) were
obtained from Sigma–Aldrich, Ireland. Clenbuterol was dissolved
in 0.89% NaCl and administered via the intraperitoneal (i.p.) route
in an injection volume of 1 ml/kg and 0.89% NaCl was administered
alone as a vehicle to control animals. LPS was administered via the
intracerebroventricular (i.c.v.) route in an injection volume of 5 lL.
2.3. Experimental design
2.3.1. Experiment I: effect of treatment with the b2-adrenoceptor
agonist clenbuterol on NFjB activity and IjBa expression in rat brain
Vehicle or clenbuterol (0.5 mg/kg; i.p.) was administered to rats
and separate groups of rats were killed 1, 4 or 8 h post clenbuterol
treatment. The brain was dissected on an ice-cold plate and corti-
cal and hippocampal tissue was harvested and rapidly frozen on
dry ice. Samples were stored at 80 C until needed for analysis
of NFjB p65 DNA binding (NFjB activity), and IjBa mRNA and
protein expression. The dose of clenbuterol employed in this study
was based on our studies demonstrating that administration of
clenbuterol (0.5 mg/kg) to rats elicits anti-inflammatory effects in
the CNS and has neuroprotective properties (Gleeson et al., 2010;
McNamee et al., 2010a,b).
2.3.2. Experiment II: can pre-treatment with b1- and b2-adrenoceptor
antagonists block the clenbuterol-induced effects on NFjB activity and
IjBa expression in rat brain?
The aim of the present study was to determine a role for the b2-
adrencoceptor in the clenbuterol-mediated effects on NFjB activ-
ity and IjBa expression. Rats were pre-treated with either vehicle
or one ofthe following drugs: the non-selective b-adrenoceptor
antagonist propranolol (10 mg/kg; i.p.), the selective b1-adreno-
ceptor antagonist metoprolol (10 mg/kg; i.p.) or the selective b2-
adrenoceptor antagonist ICI-118,551 (10 mg/kg; i.p.), 30 min prior
to i.p. administration of clenbuterol (0.5 mg/kg; i.p.). Rats were
killed 4 h post-clenbuterol injection and brain tissue was prepared
and stored as outlined in Experiment I above for analysis of NFjB
p65 DNA binding (NFjB activity) and IjBa mRNA expression.
2.3.3. Experiment III: does the b2-adrenoceptor agonists formoterol
mimic the effects of clenbuterol on NFjB activity and IjBa expression?
Rats received a vehicle or the b2-adrenoceptor agonist formo-
terol (0.5 mg/kg; i.p.) and rats were killed 4 h later. Brain tissue
was prepared and stored as outlined in Experiment I above for
analysis of NFjB p65 DNA binding (NFjB activity), and IjBamRNA
and protein expression. The dose of formoterol was employed
based on our studies demonstrating that administration of formo-
terol (0.5 mg/kg) mimicked the anti-inflammatory effects of clen-
buterol in the rat brain (McNamee et al., 2010c).
2.3.4. Experiment IV: can pre-treatment with the b2-adrenoceptor
agonist clenbuterol suppress LPS-induced NFjB activity?
Rats were pre-treated with either vehicle or clenbuterol
(0.5 mg/kg; i.p.). One hour later rats received a single intracerebro-
ventricular (icv) injection of vehicle or LPS (1 lg/5 lL) into the left
lateral ventricle. Rats were killed 2 h post-LPS treatment. Brain tis-
sue was prepared and stored as outlined in Experiment I above for
analysis of NFjB p65 DNA binding (NFjB activity), IjBamRNA and
protein, and TNF-a and ICAM-1 mRNA expression. The dose of LPS
employed and time point that animals were killed was based on a
pilot study which demonstrated that administration of LPS (1 lg/
5 lL; icv) to rats suppressed NFjB activity at a 2 h time point
post-treatment (data not shown). LPS was administered centrally
(icv) in order to avoid any contribution that peripheral
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inflammatory actions in the brain.
2.4. Intracerebroventricular surgery
Anaesthesia was induced using 5% gaseous isofluorane. Rats
were placed in a stereotaxic frame and were maintained on 2.5–
3% gaseous isofluorane. After shaving and sterilising the top of
the head a midline sagittal incision of approximately 1.5 cm in
length was made between the ears. A burr hole was drilled through
the skull over the left lateral ventricle (stereotaxic coordinates:
0.09 cm posterior to bregma, 0.14 cm left lateral to midline,
0.36 cm ventral from skull surface) through which a glass micropi-
pette delivered 5 lL of vehicle or LPS at a rate of 1 lL/min. The
micropipette was withdrawn slowly and the incision was closed
up using surgical staples. The rat was removed from the stereotaxic
frame and singly housed while recovering from anaesthesia.
2.5. Measurement of NFjB activity
Nuclear fractions were prepared from homogenised cortex and
hippocampus using an NE-PER Nuclear and Cytoplasmic Extraction
kit (Thermo Scientific Pierce, UK) according to manufacturer’s
instructions. Protein concentrations were measured in the nuclear
extracts using the Pierce BCA protein assay kit (Thermo Scientific
Pierce, UK), and the protein content was equalised across all sam-
ples. NFjB p65 subunit DNA binding in nuclear fractions was mea-
sured using an NFjB p65 chemiluminescent transcription factor kit
(Thermo Scientific Pierce, UK) as per manufacturer’s instructions,
and NFjB activity was expressed as Relative Light Units (RLU)/lg
protein.
2.6. Analysis of gene expression of IjB and NFjB-inducible genes by
real-time PCR
RNAwas extracted from brain tissue using the NucleoSpin RNA
II total RNA isolation kit (Macherey–Nagel, Germany). Any genomic
DNA contamination was removed with the addition of DNase to the
samples according to the manufacturer’s instructions. RNA was re-
verse transcribed into cDNA using a High Capacity cDNA Archive
Kit (Applied Biosystems, Darmstadt, Germany). Real-time PCR was
performed using an ABI Prism 7300 instrument (Applied Biosys-
tems) as previously described (Boyle and Connor, 2007). Taqman
Gene Expression Assays (Applied Biosystems) containing forward
and reverse primers and a FAM-labeled MGB Taqman probe were
used to quantify the gene of interest. The assay ID’s for the gene
expression assays employed were (IjBa: Rn01473658_g1; IjBb:
Rn00578384_m1; TNF-a: Rn99999017_m1; ICAM-1:
Rn00564227_m1). PCR was performed using Taqman Universal
PCRMasterMix and sampleswere run in duplicate. The cycling con-
ditions consisted of 90 C for 10 min and 40 cycles of 90 C for 15 s
followed by 60 C for 1 min. b-actinwas used as an endogenous con-
trol to normalise gene expressiondata. Relative gene expressionwas
calculated using the DDCT method with Applied BioSystems RQ
software (Applied BioSystems, UK).
2.7. Analysis IjBa protein expression and IjBa phosphorylation using
Western immunoblotting
Cytoplasmic fractions were prepared from homogenised cortex
and hippocampus using an NE-PER Nuclear and Cytoplasmic
Extraction kit (Thermo Scientific Pierce, UK) according to manufac-
turer’s instructions. Protein concentrations were measured in the
cytoplasmic extracts using the Pierce BCA protein assay kit (Ther-
mo Scientific Pierce, UK), and the protein content was equalizedacross all samples. Each sample was combined with sample buffer
[0.5 M Tris–HCl, pH 6.8; 10% (w/v) sodium dodecyl sulphate; 10%
(v/v) glycerol; 5% (v/v) b-mercaptoethanol; 0.05% (w/v) bromophe-
nol blue] in a 1:1 ratio. Samples were heated at 65 C for 5 min
prior to being loaded on the polyacrylamide gel.
Proteins were separated on a 10% SDS–polyacrylamide gel by
application of a constant voltage of 40 mA and transferred onto a
PVDF membrane via the semi-dry transfer method (225 mA for
50 min). To assess the expression of total-IjBa and phosphory-
lated-IjBa, PVDF membranes were incubated with primary anti-
body overnight at 4 C. The primary antibodies used were: IjBa
(L35A5) mouse mAb antibody, and Phospho-IjB-a (Ser32)
(14D4) antibody (Cell Signaling) diluted 1:1000 in TBS/Tween
(0.1% v/v) containing 5% BSA. Immunoreactive bands were de-
tected using a peroxidase-linked donkey anti-rabbit IgG antibody
(Amersham Biosciences) diluted 1:5000 in TBS/Tween (0.1% v/v)
containing 1% BSA. PVDF membranes were stripped using ReBlot
Plus (Chemicon) and probed with monoclonal mouse IgG antibody
that targets actin (Sigma, UK) diluted 1:1000 in TBS/Tween (0.1% v/
v) containing 1% BSA, and immunoreactive bands were detected
using a peroxidase-linked goat anti-mouse IgG antibody (Sigma,
UK) diluted 1:5000 in TBS/Tween (0.1% v/v) containing 1% BSA.
Protein bands were visualised using Immobilon Western Chemilu-
minescent HRP Substrate (Millipore). Bands were quantified by
densitometric analysis using ImageJ software (Wayne Rasband,
NIH, USA).
2.8. Statistical analysis of data
All values are expressed as mean ± standard error of the mean
(SEM). Data was analysed using a Student’s t-test, one-way or
two-way analysis of variance (ANOVA) followed, where appropri-
ate, by a Dunnet’s or Newman–Keuls post hoc test (GB-Stat). A va-
lue of p < 0.05 was considered to be statistically significant.
3. Results
3.1. Clenbuterol suppresses NFjB activity and increases IjBa
expression under normal resting conditions in the rat brain
3.1.1. The b2-adrenoceptor agonist clenbuterol suppresses NFjB
activity
Administration of the long-acting brain-penetrant b2-adreno-
ceptor agonist clenbuterol (0.5 mg/kg; i.p.) induced a time-depen-
dent suppression of NFjB p65 DNA binding activity (NFjB activity)
in nuclear fractions of cortex and hippocampus (Fig. 1a and b). The
suppression of NFjB activity was maximal at 4 h post-treatment
(p < 0.01). Consistent with these results, a one-way ANOVA
revealed a significant effect of clenbuterol on NFjB activity in both
the cortex [F(3,17) = 5.25, p = 0.0095] and hippocampus [F(3,17) =
15.72, p < 0.0001].
3.1.2. The b2-adrenoceptor agonist clenbuterol induces IjBa gene
expression
Rat cortex and hippocampus were examined for inhibitory IjB
expression 1, 4 and 8 h following clenbuterol (0.5 mg/kg; i.p.)
administration. In keeping with findings by McNamee et al.
(2010c) the present study found a robust and transient increase
in IjBa mRNA (p < 0.01) 1 h post-clenbuterol administration in
both cortex and hippocampus (Fig. 1c and d) and we also found a
modest and transient increase in IjBb mRNA to a lesser extent
(data not shown). Consistent with these results, a one-way ANOVA
revealed a significant effect of clenbuterol on IjBa mRNA in both
the cortex [F(3,14) = 3.72, p = 0.0372] and hippocampus [F(3,16) =




Fig. 1. The b2-adrenoceptor agonist clenbuterol suppresses NFjB activity and increases IjBa expression in a time-dependent manner, in cortex and hippocampus.
Clenbuterol (0.5 mg/kg; i.p.) or vehicle (0.89% w/v saline; i.p.) was administered to rats which were sacrificed at 1, 4 and 8 h time points post-injection. Clenbuterol induced a
time-dependent suppression of NFjB p65 binding (NFjB activity) in rat cortex (a) and hippocampus (b). Clenbuterol induced a time-dependent increase in IjBa mRNA
expression in cortex (c) and hippocampus (d) and an increase in IjBa protein expression in cortex (e) and hippocampus (f). Data expressed as mean + SEM (n = 5–6). mRNA
data expressed as fold-change vs. saline vehicle. Results presented in upper panels (e and f) are representative images of Western immunoblots. ⁄p < 0.05, ⁄⁄p < 0.01 vs. saline
vehicle (One-way ANOVA followed by post hoc Dunnett’s procedure).
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expression
induction of IjBa mRNA was followed by a time-dependent
increase in IjBa protein production 4 h post-clenbuteroltreatment in cortex (p < 0.01) and hippocampus (p < 0.05)
(Fig. 1e and f). Notably, this increase in IjBa protein mirrors
the time-dependent decrease in NFjB activity seen in Fig. 1(a)
and (b) 4 h after clenbuterol treatment. Thus, the increase in IjBa
372 K.J. Ryan et al. / Neurochemistry International 63 (2013) 368–378protein expression coincides with the suppression of NFjB
activity.
3.2. The effects of clenbuterol on NFjB activity and IjBa expression
are mediated by the b2-adrenoceptor3.2.1. Pharmacological antagonism of b2-adrenoceptors blocks the
ability of clenbuterol to suppress NFjB activity and to induce IjBa
expression
The clenbuterol-induced suppression of NFjB activity (p < 0.05)
was blocked by pre-treatment with the non-selective b-adrenocep-
tor antagonist propranolol and the selective b2-adrenoceptor
antagonist ICI-118,551 in both cortex and hippocampus (Fig. 2a
and b). Similarly, the clenbuterol-induced increase in IjBa expres-
sion (p < 0.01) was prevented by propranolol and ICI-118,551 pre-
treatment cortex and hippocampus (Fig. 2c and d). In contrast, pre-
treatment with the b1-adrenoceptor antagonist metoprolol had no
effect on the clenbuterol-induced changes in NFjB activity or IjBa
expression (Fig. 2a–d). This clearly shows that the ability of clenbu-
terol to suppress NFjB activity and increase IjBa expression is
mediated specifically by the central b2-adrenoceptor subtype. Con-
sistent with these findings a one-way ANOVA revealed a significant
effect of drug treatment on NFjB activity in cortex [F(4,21) = 3.94,
p = 0.0154] and hippocampus [F(4,21) = 5.53, p = 0.0033] and on
IjBa mRNA expression in cortex [F(4,23) = 17.97, p < 0.0001] and
hippocampus [F(4,23) = 8.31, p = 0.0003].(a) (
(c) (
Fig. 2. Clenbuterol-induced suppression of NFjB activity and induction of IjBamRNA ex
Rats were pre-treated with the non-selective b-adrenoceptor antagonist propranolol (10
the selective b2-adrenoceptor antagonist ICI-118,551 (10 mg/kg; i.p.) 30 min prior to cl
ability of clenbuterol to suppress NFjB activity and increase IjBamRNA expression was p
cortex (a and c) and hippocampus (b and d). Data expressed as mean + SEM (n = 5–6). m
vehicle; ++p < 0.01, vs. clenbuterol vehicle (One-way ANOVA followed by post hoc Newm3.2.2. The selective b2-adrenoceptor agonist formoterol mimics the
ability of clenbuterol to suppress NFjB activity and to induce IjBa
expression
A Student’s t-test demonstrated that formoterol suppressed
NFjB activity in both cortex and hippocampus 4 h post-adminis-
tration (p < 0.001) (Fig. 3a and b), and induced an increase in IjBa
mRNA (p < 0.01) and protein (p < 0.05) in both regions (Fig. 3c–f).3.3. Pre-treatment with the b2-adrenoceptor agonist clenbuterol
suppresses LPS-induced NFjB activity, IjBa phosphorylation and
degradation
The LPS-induced increase in NFjB activity (p < 0.01) was signif-
icantly attenuated (p < 0.01) by clenbuterol pre-treatment in cor-
tex and hippocampus (Fig. 4a and b). Consistent with this
finding, a two-way ANOVA revealed a significant clenbuterol  LPS
interaction in both cortex [F(1,18) = 19.14, p = 0.0004] and hippo-
campus [F(1,18) = 5.74, p = 0.0277]. Notably, the LPS-induced phos-
phorylation of IjBa, which is responsible for NFjB activation,
was also blocked by clenbuterol pre-treatment in cortex and hip-
pocampus (p < 0.05) (Fig. 4c and d) where a two-way ANOVA re-
vealed a significant clenbuterol  LPS interaction in cortex
[F(1,18) = 3.87, p = 0.0069] and a significant effect of clenbuterol in
hippocampus [F(1,15) = 1.88, p = 0.0493].
In addition, the LPS-induced suppression of IjBa protein
(p < 0.01) was reversed by clenbuterol pre-treatment in cortex
(p < 0.01) and hippocampus (p < 0.05) (Fig. 4e and f). Consistentb)
d)
pression is mediated specifically by the b2-adrenoceptor in cortex and hippocampus
mg/kg; i.p.), the selective b1-adrenoceptor antagonist metoprolol (10 mg/kg; i.p.) or
enbuterol (0.5 mg/kg; i.p.). Rats were sacrificed 4 h post clenbuterol injection. The
revented by pre-treatment with propranolol and ICI-118,551, but not metoprolol in





Fig. 3. The b2-adrencoceptor agonist formoterol suppresses NFjB activity and increases IjBa expression in cortex and hippocampus. Formoterol (0.5 mg/kg; i.p) or vehicle
(0.89% w/v saline; i.p) were administered and rats were sacrificed 4 h post-injection. Formoterol suppressed NFjB activity in cortex (a) and hippocampus (b). Formoterol also
increased IjBa mRNA expression in cortex (c) and hippocampus (d), and IjBa protein expression in cortex (e) and hippocampus (f). Data expressed as mean + SEM (n = 6).
mRNA data expressed as fold-change vs. saline vehicle. Results presented in upper panels (e and f) are representative images of Western immunoblots. ⁄p < 0.05, ⁄⁄p < 0.01,
⁄⁄⁄p < .001 vs. saline vehicle [Student’s t-test].
K.J. Ryan et al. / Neurochemistry International 63 (2013) 368–378 373with this finding, a two-way ANOVA revealed a significant effect of
clenbuterol on IjBa protein expression in cortex [F(1,18) = 27.13,
p = 0.0003] and hippocampus [F(1,18) = 6.95, p = 0.0299].
3.4. Pre-treatment with the b2-adrenoceptor agonist clenbuterol
suppresses LPS-induced expression of the NFjB-inducible genes TNF-a
and ICAM-1
Consistent with the finding that clenbuterol suppresses LPS-in-
duced NFjB activity, we also found that clenbuterol suppresses
expression of the NFjB-inducible genes TNF-a and ICAM-1 in-
duced by LPS in rat brain. The robust LPS-induced increase in
TNF-amRNA was significantly attenuated byclenbuterol pre-treat-
ment in cortex (approximately 70% attenuation; p < 0.01) and in
hippocampus (approximately 50% attenuation; p < 0.01) (Fig. 5a
and b). Similarly, LPS-induced ICAM-1 mRNA was significantlyattenuated by clenbuterol pre-treatment in both regions
(p < 0.01) (Fig. 5c and d). Consistent with these findings, a two-
way ANOVA revealed a significant clenbuterol  LPS interaction
for both TNF-a [cortex: F(1,18) = 13.88, p = 0.0015; hippocampus:
F(1,18) = 17.97, p = 0.0005] and ICAM-1 [cortex: F(1,18) = 17.88,
p = 0.0005; hippocampus: F(1,18) = 6.29, p = 0.022].4. Discussion
An increasing body of evidence indicates that noradrenaline via
an action on glial b2-adrenoceptors elicit endogenous anti-inflam-
matory actions in the brain (Feinstein et al., 2002; Heneka et al.,
2002; Mori et al., 2002; Kalinin et al., 2007; McNamee et al.,
2010a). Here we demonstrate that direct stimulation of central




Fig. 4. Pre-treatment with the b2-adrenoceptor agonist clenbuterol suppresses LPS-induced NFjB activation and blocks LPS-induced IjBa phosphorylation and degradation
in cortex and hippocampus. Clenbuterol (0.5 mg/kg; i.p.) or vehicle (0.89% w/v saline; i.p.) were administered 1 h prior to LPS (1 lg/5 lL; i.c.v.) or vehicle (0.89% w/v saline;
i.c.v.). Rats were sacrificed 2 h post LPS injection. Clenbuterol pre-treatment significantly attenuated LPS-induced NFjB activity in cortex (a) and hippocampus (b). Pre-
treatment with clenbuterol attenuated the LPS-induced phosphorylation of IkBa in both cortex (c) and hippocampus (d). The LPS-induced decrease in IjBa protein was also
blocked by clenbuterol pre-treatment in cortex (e) and hippocampus (f). Data expressed as mean + SEM (n = 5–6). Results presented in upper panels (above c and d) are
representative images of Western immunoblots. ⁄p < 0.05, ⁄⁄p < 0.01 vs. saline vehicle; +p < 0.05, ++p < 0.01 vs. LPS vehicle (Two-way ANOVA followed by post hoc Newman–
Keuls test).
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brain under normal (non-inflammatory) conditions, as well as in
response to an inflammatory stimulus (bacterial LPS). We also
demonstrate that clenbuterol increases expression of the inhibi-
tory IjBa protein, a result that supports our earlier finding that
clenbuterol induced IjBamRNA expression in rat brain (McNamee
et al., 2010c). Time-course analysis of the actions of clenbuterol on
IjB expression and NFjB activity demonstrates a robust early
induction of IjBa mRNA expression peaking 1 h post-clenbuteroladministration, followed by an increase in de novo synthesis of
IjB protein expression and parallel suppression of NFjB activity
at 4 and 8 h post-clenbuterol administration. Thus a single admin-
istration of clenbuterol induces a sustained suppression of NFjB
activity that persists for at least 8 h post-administration which is
paralleled by an increase in the inhibitory IjBa protein in the cyto-
sol. In contrast to the robust increase in IjBa expression observed
following clenbuterol treatment (3–3.3-fold), a very small and
transient increase (approximately a 1.15 increase evident only at
(a) (b)
(c) (d)
Fig. 5. Pre-treatment with the b2-adrenoceptor agonist clenbuterol suppresses LPS-induced expression of the NFjB-inducible genes TNF-a and ICAM-1 in cortex and
hippocampus. Clenbuterol (0.5 mg/kg; i.p.) or vehicle (0.89% w/v saline; i.p.) were administered 1 h prior to LPS (1 lg/5 lL; i.c.v.) or vehicle (0.89% w/v saline; i.c.v.). Rats were
sacrificed 2 h post LPS injection. Pre-treatment with the b2-adrenoceptor agonist clenbuterol significantly attenuated the LPS-induced increase in TNF-amRNA expression in
cortex (a) and hippocampus (b), and ICAM-1 mRNA expression in cortex (c) and hippocampus (d). Data expressed as mean + SEM (n = 5–6). mRNA data expressed as fold
change compared to control. ⁄⁄p < 0.01 vs. saline vehicle; +p < 0.05, ++p < 0.01 vs. LPS vehicle (Two-way ANOVA followed by post hoc Newman–Keuls test).
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treatment (data not shown). Whilst the clenbuterol-induced in-
crease in IjBb expression was statistically significant in the cortex
and approaching statistical significance in the hippocampus, the
small magnitude of the increases observed suggest that a role for
IjBb in the suppressive effect of clenbuterol on NFjB expression
is unlikely. Based on the magnitude of the increase of IjBa expres-
sion and the time-course of the response, we suggest that the in-
crease in cytosolic IjBa protein observed at 4 and 8 h mediates
the suppressive effect of clenbuterol on NFjB activity by seques-
tering NFjB p65 in the cytoplasm and preventing its translocation
to the nucleus. In addition, IjBa has the ability to terminate NFjB
activity by interacting with NFjB and transporting it back to the
cytoplasm where is resides in an inactive form bound to IjBa
(Arenzana-Seisdedos et al., 1995, 1997). This is a plausible mecha-
nism behind the clenbuterol-induced suppression of NFjB activity
as even a small (2-fold) increase in cytoplasmic IjBa (which is
similar to the level induced by clenbuterol) is known to substan-
tially inhibit NFjB activation (Miyamoto et al., 1994). While the
exact mechanism by which clenbuterol induces de novo synthesis
of IkBa remains to be clarified, it is likely to involve an increase in
intracellular concentrations of cAMP which is long known to sup-
press immune responses (Rappaport and Dodge, 1982; Hasler
et al., 1983; Gerlo et al., 2011). cAMP may suppress NFjB activa-
tion at the level of the differential binding of CREB and NFjB to
the CREB-binding protein, which is necessary for efficient gene
transcription (Parry and Mackman, 1997; Wen et al., 2010). Addi-
tionally, protein kinase A (PKA) which is activated by cAMP, has
been reported to inhibit translocation of NFjB p65 to the nucleus
by stabilisation of IjBa concentrations and blocking its phosphor-
ylation in T-cells (Neumann et al., 1995). Given that clenbuterol
and other b2-adrenoceptor agonists signal via intracellular cAMPand activation of PKA (Ordway et al., 1987), it is possible that sim-
ilar mechanisms are involved in the clenbuterol-induced suppres-
sion of NFjB.
Under normal circumstances, there is a natural increase in IjBa
protein synthesis following NFjB activation, due to the presence of
a transcriptional binding site for IjBa on the NFjB promoter (Sun
et al., 1993), and this serves as a negative feedback mechanism to
prevent over-activation of NFjB. Thus, the results presented here
suggest that agents that are capable of increasing IjBa expression,
such as the b2-adrenoceptor agonist clenbuterol, may be useful in
combating neuroinflammatory disorders where NFjB is dysregu-
lated, such as in Alzheimer’s disease (Kaltschmidt et al., 1999). In
this regard, it is thought that activation of NFjB plays a role in
the early phases of Alzheimer’s disease when initiation of neuritic
plaques and neuronal apoptosis occurs (Kaltschmidt et al., 1999).
Our group and others have shown that the effects of clenbuterol
on cytokine expression in the CNS are mediated specifically by the
b2-adrenoceptor subtype (Junker et al., 2002; Culmsee et al., 2007;
McNamee et al., 2010a). The findings from the present study dem-
onstrate, through the use of selective and non-selective antago-
nists for b1- and b2-adrenoceptor subtypes, that the effect of
clenbuterol on NFjB activity and IjBa expression is mediated by
the b2-adrenoceptor. These data are important in highlighting the
specific role of b-adrenoceptor activation in the actions of clenbu-
terol on NFjB, as previous studies indicate that clenbuterol can eli-
cit biological responses independent of b-adrenoceptors (Desaphy
et al., 2003; Ngala et al., 2009). Furthermore we demonstrate that
treatment with the related long-acting b2-adrenoceptor agonist
formoterol mimicked the ability of clenbuterol to suppress NFjB
activity and upregulate IjBa. The fact that formoterol shares the
ability of clenbuterol to suppress NFjB activity in the brain is of
significance from a clinical perspective, as formoterol is currently
376 K.J. Ryan et al. / Neurochemistry International 63 (2013) 368–378widely used for the treatment of asthma in humans (Welsh and
Cates, 2010), whereas clenbuterol’s use is confined to the veteri-
nary setting (Erichsen et al., 1994). Combined with our previous
finding that systemic formoterol treatment increases expression
of the anti-inflammatory cytokine IL-10 in rat brain (McNamee
et al., 2010a,b,c), these data further support the notion that formo-
terol can penetrate that brain following systemic administration.
Taken together these data further reinforce the argument for the
b2-adrenoceptor as a neuroprotective target, and the ability of b2-
adrenoceptor activation within the CNS to suppress activity of
NFjB independent of an immune stimulus adds to the hypothesis
that increases in central noradrenergic tone and b2-adrenoceptor
activation provides an endogenous immunomodulatory mecha-
nism within the brain to self-regulate inflammation.
As well as its ability to suppress NFjB activity under normal
(non-inflamed) conditions in the rat brain, our data clearly shows
for the first time, that clenbuterol suppresses NFjB activation that
occurs in response to inflammation. It has been well documented
that LPS treatment leads to phosphorylation and degradation of
IjBa protein, thus freeing NFjB and allowing it to translocate to
the nucleus where it induces transcription of pro-inflammatory
genes (Karin and Ben-Neriah, 2000). Pre-treatment with clenbuter-
ol significantly attenuated LPS-induced activation of NFjB in rat
cortex and hippocampus. In tandem with this we found that clen-
buterol blocked the LPS-induced phosphorylation of IjBa and its
degradation. This lends support to our hypothesis that clenbuterol
may inhibit nuclear translocation of NFjB through stabilisation of
IjBa by blocking its phosphorylation (Fig. 6), in a similar manner
to that seen in T-cells (Neumann et al., 1995). We hypothesise that
by blocking IjBa phosphorylation, clenbuterol not only limits
NFjB activity but also limits its downstream signalling as seenFig. 6. Proposed mechanism by which b2-adrenoceptor stimulation inhibits NFjB activit
synthesis of IkBa under basal conditions while Fig. 6b shows the additional clenbute
phosphoylation.by the ability of clenbuterol to suppress LPS-induced TNF-a and
ICAM-1, two NFjB-inducible genes.
Clenbuterol suppresses NFjB via de novo synthesis of IjBa
through induction of gene expression under basal and LPS-stimu-
lated conditions. Additionally under LPS-stimulated conditions,
clenbuterol suppresses NFjB by stabilisation of IjBa by inhibition
of its phosphorylation. It is however possible that pathways lead-
ing to stabilization of IkBa are also activated by clenbuterol under
basal conditions but are not detectable given that basal expression
is low (see faint representative bands in Fig. 4). An inflammatory
stimulus (LPS) however initiates phosphorylation and changes
are more readily detected.
From previous pilot investigations we determined that LPS-in-
duced NFjB activity in the cortex peaks 2 h post-LPS and accord-
ingly, this time was chosen as an appropriate point to assess the
effects of clenbuterol on IjBa and NFjB under inflammatory con-
ditions (Fig. 4). Clenbuterol is capable of suppressing NFjB activa-
tion over a time course from 1 to 4 h (Fig. 1) and based on this
profile samples were taken 3 h post clenbuterol. However when
tested under basal conditions the 3 h pre-treatment had no effect
on NFjB binding. More robust reductions in NFjB binding are ob-
tained at the 4 and 8 h time points (Fig. 1a and b) so it may be that
the 3 h time point may have been too early to detect a reduction
under basal conditions (as presented in Fig. 4). In any case pre-
treatment with clenbuterol suppresses LPS-induced NFjB activa-
tion at this time.
Ubiquitination regulates at least three steps in the NFjB path-
way. IjBa protein phosphorylation and degradation, the process-
ing of NFjB precursors and activation of the IkB kinase (IKK)
(reviewed by O’Donnell and Ting, 2012). Therefore, it is possible
that clenbuterol may suppress NFjB activation not only via induc-y under (a) basal and (b) inflammatory conditions. Suppression of NFjB via de novo
rol related suppression of NFkB by stabilisation of IkBa and prevention of IkBa
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phosphorylation. The delayed appearance of IjBa protein in the
cytoplasm following mRNA expression indicates that inhibition
of kinases upstream of NFjB may play a role in the prevention of
IjBa degradation. In this regard, it has previously been reported
that clenbuterol up-regulates the expression of the anti-apoptotic
proteins BCL-2 and BCL-XL (Zhu et al., 1999) which are known in
turn to prevent IjBa degradation to effect an anti-inflammatory
action mediated by the inhibition of NFjB (Badrichani et al.,
1999). In addition, several groups have reported that the broad-
spectrum anti-inflammatory cytokine IL-10 is capable of reducing
NFjB activity, not only through prevention of IjBa phosphoryla-
tion, but also by blocking IKK upstream of IjBa (Shames et al.,
1998; Schottelius et al., 1999). Previous data from our group dem-
onstrates that clenbuterol is an inducer of IL-10 and so it is possible
that the suppressive effects of clenbuterol on NFjB activity may be
mediated through the IKK complex (McNamee et al., 2010b).
The results of the present study support other work which
implicates the regulation of NFjB activity in the anti-inflammatory
effects of b2-adrenoceptor agonists (Farmer and Pugin, 2000).
Over-activation of the NFjB pathway is a pathogenic feature of
neuroinflammatory disorders such as Alzheimer’s disease (Kaltsch-
midt et al., 1999). In this regard, it is thought that activation of
NFjB plays a role in the early phases of Alzheimer’s disease when
initiation of neuritic plaques and neuronal apoptosis occurs (Kal-
tschmidt et al., 1999). Thus, methods which inhibit NFjB may be
a useful therapeutic tool in acute and chronic diseases where the
inflammatory response becomes dysregulated. At present we are
unable to confirm the specific cell type mediating these events.
However, evidence suggests that b2-adrenoceptors are found pre-
dominantly on astrocytes and microglia within the CNS (Zeinstra
et al., 2002). of b2-adrenoceptor we suspect that glial cells may
be playing a role given the body of evidence which indicates that
noradrenaline via an action on glial b2-adrenoceptors elicit endog-
enous anti-inflammatory actions in the brain (Feinstein et al.,
2002; Heneka et al., 2002; Mori et al., 2002; Kalinin et al., 2007;
McNamee et al., 2010a). Future work, perhaps using single cell cul-
ture of glial cells, should be performed to show specifically where
these events occur. The results of this study demonstrate that b2-
adrenoceptor activation inhibits NFjB activation and the induction
of NFjB-inducible genes that occurs in response to an inflamma-
tory stimulus. Thus, targeting the b2-adrenoceptor is a potential
mechanism to selectively target NFjB activity.Acknowledgments
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